Refractory Adult Acute Lymphoblastic Leukemia

7 clinical trials · Condition

Record	Firm	Date
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant (NCT03326921)	Fred Hutchinson Cancer Center	2018-02-23
huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia (NCT03103971)	Fred Hutchinson Cancer Center	2017-11-03
Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (NCT02819804)	Northwestern University	2017-08-17
Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (NCT02484430)	National Cancer Institute (NCI)	2017-04-06
Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (NCT02861040)	Northwestern University	2016-08-01
Personalized NK Cell Therapy in CBT (NCT02727803)	M.D. Anderson Cancer Center	2016-05-19
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children (NCT01858740)	Fred Hutchinson Cancer Center	2014-04-10

Every clearance here is in the API, with alerts when new ones post.